Company intelligence / Profile preview

Young Owl Microfluidics

London, England, United Kingdomgtr.ukri.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Young Owl Microfluidics has developed a modular, scalable microfluidic device designed to accelerate rapid and high-throughput drug testing across all stages of therapeutic development. The platform supports applications in biocatalysis, regenerative medicine, pharmaceutical research, organoid culture, and more. The company is an active UCL spin-out with strong academic roots and ongoing collaborations in the UK life sciences ecosystem. No clinical results are reported as it is a platform/device company.

Modalities: Device
Industry: Non-Drug Biotech

Partnerships

No major pharma/biotech partnerships publicly disclosed as of June 2025. Academic collaboration with University College London is central.

Beyond the preview

Go deeper on Young Owl Microfluidics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Young Owl Microfluidics.

Explore the full profile